Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
DULOXETINE (DULOXETINE HYDROCHLORIDE)
ELI LILLY CANADA INC
N06AX21
DULOXETINE
60MG
CAPSULE (DELAYED RELEASE)
DULOXETINE (DULOXETINE HYDROCHLORIDE) 60MG
ORAL
7/28
Prescription
SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0152350002; AHFS:
APPROVED
2007-11-01
_CYMBALTA_ _®_ _ Product Monograph _ _Page 1 of 79 _ PRODUCT MONOGRAPH PR CYMBALTA ® Duloxetine Delayed Release Capsules, Mfr. Std. Duloxetine (as duloxetine hydrochloride) 30 mg and 60 mg ANALGESIC/ANTIDEPRESSANT/ANXIOLYTIC Eli Lilly Canada Inc. Date of Initial Approval: Exchange Tower October 31, 2007 130 King Street West, Suite 900 PO Box 73 Date of Revision: Toronto, Ontario March 25, 2021 M5X 1B1 1-866-364-4043 www.lilly.ca Control № : 245810 © CYMBALTA is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates _CYMBALTA_ _®_ _ Product Monograph _ _Page 2 of 79 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS ................................................................................. 5 ADVERSE REACTIONS ................................................................................................. 18 DRUG INTERACTIONS ................................................................................................. 37 DOSAGE AND ADMINISTRATION ............................................................................. 40 OVERDOSAGE ................................................................................................................ 43 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 44 STORAGE AND STABILITY ......................................................................................... 47 DOSAGE FORMS, COMPOSITION AND PACKAGING............................................. 47 PART II: SCIENTIFIC INFORMATION .......................................................................... Baca dokumen lengkapnya